Skip to Content
Authors Aravinthan AD, Doyle AC, Issachar A, Dib M, Peretz D, Cattral MS, Ghanekar A, McGilvray ID, Selzner M, Greig PD, Grant DR, Selzner N, Lilly LB, Renner EL
Author Profile(s)
Journal Am. J. Transplant.
Publish Date 2016 Apr 18
PubMed ID 27088432

Liver transplantation (LT) is the treatment of choice for end-stage autoimmune liver diseases. However, the underlying disease may recur in the graft in some 20% of cases. The aim of this study is to determine whether LT using living donor grafts from first-degree relatives results in higher rates of recurrence than grafts from more distant/unrelated donors. 263 patients, who underwent a first LT in the Toronto liver transplant program between January 2000 and March 2015 for autoimmune liver diseases, and had at least 6 months of post-LT follow-up, were included in this study. Of these, 72 (27%) received a graft from a first-degree living-related donor, 56 (21%) from a distant/unrelated living donor and 135 (51%) from a deceased donor for PSC (n=138, 52%), PBC (n=69, 26%), AIH (n=44, 17%) and overlap syndromes (n=12, 5%). Recurrence occurred in 52 (20%) patients. Recurrence rates for each autoimmune liver disease were not significantly different after first-degree living-related, living unrelated or deceased donor LT. Similarly, time to recurrence, recurrence-related graft failure, graft survival and patient survival were not significantly different between groups. In conclusion, first-degree living-related donor LT for PSC, PBC or AIH is not associated with an increased risk of disease recurrence. This article is protected by copyright. All rights reserved. Copyright © 2017 The Board of Regents of the University of Wisconsin System